as on October 24, 2025 at 1:29 am IST
Day's Low
Day's High
3.09%
Downside
0.32%
Upside
52 Week's Low
52 Week's High
54.12%
Downside
1.96%
Upside
Check Travere Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$2.5B
EPS (TTM)
-0.2188
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-120.5M
Revenue (TTM)
333.9M
Profit Margin
-50.64%
Return On Equity TTM
-705.73%
Compare market cap, revenue, PE, and other key metrics of Travere Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $2.5B | 31.17% | NA | -50.64% | |
| BUY | $63.1B | 252.62% | -505.15 | -12.96% | |
| NA | $35.3B | NA | NA | -3.89% | |
| BUY | $109.3B | 101.55% | 30.36 | 31.86% | |
| BUY | $61.3B | 0.85% | 14.6 | 31.37% |
The Travere Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Travere Therapeutics Inc investment value today
Current value as on today
₹1,61,334
Returns
₹61,334
(+61.33%)
Returns from Travere Therapeutics Inc Stock
₹56,682 (+56.68%)
Dollar Returns*
₹4,653 (+4.65%)
Based on 22 analysts
72.73%
Buy
27.27%
Hold
0.00%
Sell
Based on 22 analysts, 72.73% of analysts recommend a 'BUY' rating for Travere Therapeutics Inc. Average target price of $35.93
Get share price movements and forecasts by analysts on Travere Therapeutics Inc.
What analysts predicted
21.68%UPSIDE
Target Price
$35.93
Current Price
$28.14
Analyzed by
22 Analysts
Target
$35.93
Travere Therapeutics Inc target price $35.93, a slight upside of 21.68% compared to current price of $28.14. According to 22 analysts rating.
Search interest for Travere Therapeutics Inc Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 11 September
Thu, 04:33 PM
-Wells Fargo raises Travere Therapeutics price target to $35, citing increased confidence in FSGS approval.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 1 month, TVTX stock has moved up by 13.4%
Revenue Rich
![]()
Revenue is up for the last 6 quarters, 41.37M → 114.44M (in $), with an average increase of 18.1% per quarter
Profit Spike
![]()
Netprofit is up for the last 3 quarters, -60.26M → -12.75M (in $), with an average increase of 134.7% per quarter
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.7% return, outperforming this stock by 4.7%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 133.8% return, outperforming this stock by 111.8%
| Organisation | Travere Therapeutics Inc |
| Headquarters | 3611 Valley Centre Drive, San Diego, CA, United States, 92130 |
| Industry | Health Technology |
| CEO | Dr. Eric M. Dube Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Jula Inrig M.D. | Chief Medical Officer |
Ms. Sandra Calvin | SVP, Corporate Controller & Chief Accounting Officer |
Ms. Nivi Nehra | Vice President of Corporate Communications & Investor Relations |
Ms. Angela Giannantonio | Chief People Officer |
Dr. Eric M. Dube Ph.D. | President, CEO & Director |
Mr. Christopher Cline C.F.A. | Chief Financial Officer |
Dr. William E. Rote Ph.D. | Chief Research Officer |
Mr. Peter Heerma | Chief Commercial Officer |
Ms. Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel & Secretary |
Mr. Casey Logan | Chief Business Officer |
Travere Therapeutics Inc share price today is $28.14 as on at the close of the market. Travere Therapeutics Inc share today touched a day high of $28.23 and a low of $27.27.
Travere Therapeutics Inc share touched a 52 week high of $28.69 on and a 52 week low of $12.91 on . Travere Therapeutics Inc stock price today i.e. is closed at $28.14,which is 1.93% down from its 52 week high and 117.97% up from its 52 week low.
Travere Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Travere Therapeutics Inc (TVTX) shares with as little as ₹87.835 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.35 in Travere Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Travere Therapeutics Inc share’s latest price of $28.14 as on October 24, 2025 at 1:29 am IST, you will get 0.3554 shares of Travere Therapeutics Inc. Learn more about
fractional shares .
Travere Therapeutics Inc stock has given 31.17% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?